Xanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia
International Journal of Molecular Sciences · 25.06.2026 · 27 (13) · 5734
DOI: 10.3390/ijms27135734 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.06.2026. Verfasst von Ghaith K Mansour und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Hauptthemen laut MEDLINE: Schizophrenia, Benzilates, Antipsychotic Agents, Muscarinic Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Schizophrenia remains a debilitating global health challenge where pharmacologic treatment has been stagnant for over seventy years, relying almost exclusively on the blockade of dopamine receptors. While this mechanism controls positive psychosis, it frequently fails to address negative symptoms or cognitive impairment and carries a significant burden of metabolic and motor adverse effects. This review evaluates the scientific and clinical validation of xanomeline–trospium (Cobenfy®; investigational name KarXT), the first approved antipsychotic with a completely non-dopaminergic mechanism of action. We synthesize data ranging from the unique structural biology of the bitopic M1/M4 muscarinic receptor agonist xanomeline to the pharmacokinetic innovation of using the peripheral antagonist trospium chloride to mitigate systemic toxicity. Comprehensive analyses of the EMERGENT clinical trial program demonstrate that this combination significantly reduces heterogeneous schizophrenia symptoms with a safety profile distinct from current standards of care, specifically avoiding weight gain and extrapyramidal movement disorders. Furthermore, we contrast this success with the recent failures of other novel mechanisms and explore the potential for precision medicine through the identification of muscarinic receptor deficit biotypes. We conclude that M1/M4 muscarinic receptor agonism represents an important advance toward circuit-based therapeutics that may help overcome some of the limitations inherent to dopamine-centered pharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
- Department of Internal Medicine, East Carolina University Medical Center, Greenville, NC 27834, USA.
ORCID-Profile: Ahmad W Hajjar, Abdullah Alissa, Hatouf H Sukkarieh
Zitieren
APA
Mansour, G. K., Hajjar, A. W., Hajjar, A. H., Alissa, A., & Sukkarieh, H. H. (2026). Xanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia. International Journal of Molecular Sciences, 27(13), 5734. https://doi.org/10.3390/ijms27135734
Vancouver
Mansour GK, Hajjar AW, Hajjar AH, Alissa A, Sukkarieh HH. Xanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia. International Journal of Molecular Sciences. 2026;27(13):5734. doi:10.3390/ijms27135734
BibTeX
@article{Mansour2026,
author = {Mansour, Ghaith K and Hajjar, Ahmad W and Hajjar, Adnan H and Alissa, Abdullah and Sukkarieh, Hatouf H},
title = {Xanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5734},
doi = {10.3390/ijms27135734}
}
EUVIMED